Vascular Endothelial growth factor A in HCV infected patients before and after treatment with DAAS and its possible relation to HCC development .

Autor: Helal, Essam M., Ibraheem, Wesam A., Sayed, Moataz M., Salama, Mohamed M., EL Ghandour, Ahmed M., Salama, Ashraf B.
Předmět:
Zdroj: QJM: An International Journal of Medicine; 2021 Supplement, Vol. 114, pi171-i171, 1p
Abstrakt: Background: HCC comprises 5.6% of all cancersworldwide representing the fifth most common cancer.It is also the second most common cause of cancer death. Objective: To study the impact of DAAs on appearance of H.C.C in HCV infected patients. Patients and Methods: After obtaining approval from the Institutional Review Board (IRB) and the Department of Internal Medicine, Ain Shams University and written informed consent obtained from all patients, this cross-sectional study was performed in Suez canal authority hospitals (Outpatient Clinic and the Inpatient Ward), at Ismailia Egypt.Sample size on 50 patients divided into 25 cases and 25 controls. Results: Our results w obtained and show that there was no statistically significant difference could be detected between HCV subdivided groups.There was statistically significant difference could be detected between HCC subdivided groups. Conclusion: Angiogenesis plays an important role in the progression of HCC. VEGF is aprimary driving force for both phisological and pathological angiogenesis and overexpression of VEGF is observed in HCC. Circulating levels of VEGF increase significantly remain high until end of treatment and decline to pretreatment level within 12 week of end of therapy.It has angiogenic properties. Elevated Circulating levels of VEGF after RF (radiofrequency) or TACE correlate with poor prognosis for patient with HCC (hepatocellular carcinoma). [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index